InvestorsHub Logo
Followers 13
Posts 2213
Boards Moderated 0
Alias Born 08/11/2017

Re: None

Thursday, 10/08/2020 7:52:06 AM

Thursday, October 08, 2020 7:52:06 AM

Post# of 1717
Cardiff Oncology initiated with an Overweight at Piper Sandler Piper Sandler analyst Joseph Catanzaro initiated coverage of Cardiff Oncology with an Overweight rating and $25 price target. Based on preclinical and clinical data, the company's lead product onvansertib is a "clearly differentiated" PLK1 inhibitor that offers selectivity and safety advantages over prior programs, Catanzaro tells investors in a research note. The analyst sees opportunity for continued share appreciation around additional validating data within colorectal cancer and potential proof-of-concept data in other mutant KRAS settings.

Read more at:
https://thefly.com/n.php?id=3171766

MegaDeath, changed due to circumstances of COVID-19 pandemic.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRDF News